JLABS @ BE will continue to benefit from 2.1 million euros of financial support granted by the European Regional Development Fund (ERDF) and the government agency Flanders Innovation & Entrepreneurship (VLAIO –Hermesfonds) in 2017.
Head of Johnson & Johnson Innovation
As the first JLABS in Europe, JLABS @ BE accommodates up to 30 life science startups focused on innovations across the entire healthcare spectrum, including pharmaceuticals, medical devices, consumer and health technology sectors.
JLABS @ BE is located at the heart of the Beerse Janssen R&D Campus where Dr. Paul Janssen – one of the 20th century's most innovative and productive pharmaceutical researchers – first established Janssen Pharmaceutica N.V. more than six decades ago, laying the foundation for the discovery and development of more than 80 new medicines during his lifetime.
Apply to become a resident company today to bring much needed solutions to patients and consumers.
With the growth of pharma and biotech in Europe expected to grow from €169 Billion just a few years ago to €206 Billion by 2022 (Evaluate Ltd), there has never been a better time for a new European start-up to turn their great idea into the next game-changing app, therapy, medical device, pharmaceutical, or discovery.
Inspired by Dr. Janssen's famous call-to-action, “The patients are waiting," the goal of JLABS @ BE is to attract the best and brightest talent in science and technology, and to work with European partners in healthcare to help start new, highly innovative companies, providing a wealth of incubation options for our partners and insights to new innovation for our businesses around the globe.